Over the past three months, shares of
Incyte Genomics (INCY) significantly rose by
19.6% due to factors not stated. Yet, within a week the surge exceeds
7%. Incyte's Executive Vice President,
Barry P. Flannelly, sold
1,306 shares of company stock. Notably, renowned investor
Cathie Wood's ARK ETFs adjusted their holdings by dispensing off UiPath and Incyte stocks.
Caris Life Sciences entered into a broad Precision Medicine Partnership with Incyte to enhance Incyte's Oncology Pipeline. Incyte's earnings are expected to grow, but their Q1 earnings and revenues fell below the estimates. A significant
plummet of 29.6% was reported in Incyte's stock year to date. In the meantime,
Baker Bros. Advisors saw a massive payoff with the sale of Pharmacyclics Inc; Incyte was among the fund's other top picks.
Incyte Genomics INCY News Analytics from Thu, 05 Mar 2015 08:00:00 GMT to Thu, 18 Jul 2024 12:01:12 GMT -
Rating 6
- Innovation 2
- Information 5
- Rumor -4
